Targets › IGSF8
1 program from 1 company in 2 trials: 1 Phase 2, 1 Phase 1; Ophthalmology; next expected readout Jan 2027.
Member of the immunoglobulin superfamily (IgSF) that links tetraspanin-enriched microdomains to the actin cytoskeleton and plays several important roles in innate and adaptive immunity. Acts as an inducible receptor of HSPA8 on dendritic cells to enhance the CCL21/SLC-dependent migration of activated mature dendritic cells while attenuating their antigen-specific stimulatory capacities. (UniProt, Q969P0)
Open in Phaseline: the race on IGSF8, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Amgen | AMG 732 Insulin Growth Factor-1 Receptor (IGF-1R) pathway inhibitor via IGSF8 binding | IGSF8 | Phase 2 | Thyroid Eye Disease | Jan 2027 |
Thyroid Eye Disease (2)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.